Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Harler

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Infusionstherapie Und Klinische Ernahrung|June 1, 1975
[Infusion therapy in uretero-enterostomy]R Stark, B Harler
Shock (Augusta, Ga.)|January 5, 2002
Increased neutrophil motility by beta-glucan in the absence of chemoattractantM B Harler, J Reichner
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|June 1, 1976
[Trans-jugular retrograde portography. Preliminary communication]M Thelen, R Janson, D Schulz, et al.
Molecular Biology of the Cell|October 8, 1998
Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migrationR L Yauch, F Berditchevski, M B Harler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 3, 1999
Promotion of neutrophil chemotaxis through differential regulation of beta 1 and beta 2 integrinsM B Harler, E Wakshull, E J Filardo, et al.
Transplantation Proceedings|July 1, 2008
Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trialsL Demopoulos, M Polinsky, G Steele, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 22, 2014
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized studyG B Klintmalm, S Feng, J R Lake, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 14, 2011
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipientsF Vincenti, C P Larsen, J Alberu, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2012
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneysJ O Medina Pestana, J M Grinyo, Y Vanrenterghem, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Infusionstherapie Und Klinische Ernahrung|June 1, 1975
[Infusion therapy in uretero-enterostomy]R Stark, B Harler
Shock (Augusta, Ga.)|January 5, 2002
Increased neutrophil motility by beta-glucan in the absence of chemoattractantM B Harler, J Reichner
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|June 1, 1976
[Trans-jugular retrograde portography. Preliminary communication]M Thelen, R Janson, D Schulz, et al.
Molecular Biology of the Cell|October 8, 1998
Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migrationR L Yauch, F Berditchevski, M B Harler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 3, 1999
Promotion of neutrophil chemotaxis through differential regulation of beta 1 and beta 2 integrinsM B Harler, E Wakshull, E J Filardo, et al.
Transplantation Proceedings|July 1, 2008
Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trialsL Demopoulos, M Polinsky, G Steele, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 22, 2014
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized studyG B Klintmalm, S Feng, J R Lake, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 14, 2011
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipientsF Vincenti, C P Larsen, J Alberu, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2012
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneysJ O Medina Pestana, J M Grinyo, Y Vanrenterghem, et al.
Pageof 1